OHR PHARMACEUTICAL INC. STOCK OPTION AGREEMENTStock Option Agreement • March 8th, 2019 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • New York
THIS AGREEMENT, made and entered into as of [_______________] (the “Date of Grant”) between OHR PHARMACEUTICAL, INC., a Delaware corporation (herein called the “Corporation”), and [_____________] (herein called the “Optionee”).
NEUBASE THERAPEUTICS, INC. AMENDMENT TO RESTRICTED STOCK PURCHASE AGREEMENTRestricted Stock Purchase Agreement • March 8th, 2019 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • Delaware
This Amendment to that certain Restricted Stock Purchase Agreement dated as of September 6, 2018 by and between NeuBase Therapeutics, Inc. (the “Company” and Dietrich A. Stephan (the “Purchase”) (the “RSPA”), is made as of December 26, 2018 (this “Amendment”). The Company and the Purchaser may be hereinafter referred to individually as a “Party” and together as the “Parties” All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the RSPA.
NEUBASE THERAPEUTICS, INC. RESTRICTED STOCK PURCHASE AGREEMENTRestricted Stock Purchase Agreement • March 8th, 2019 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • Delaware
This Restricted Stock Purchase Agreement (the “Agreement”) is made as of September 6, 2018 by and between NeuBase Therapeutics, Inc., a Delaware corporation (the “Company”), and Dietrich A. Stephan (the “Purchaser”).
LICENSE AGREEMENT Carnegie Mellon University – NeuBase Therapeutics, Inc.License Agreement • March 8th, 2019 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • Pennsylvania
This Agreement (hereinafter “this Agreement”) entered into as of 17th day of December, 2018 (“Effective Date”) by and between Carnegie Mellon University, a Pennsylvania not-for- profit corporation, having a principal place of business at 5000 Forbes Avenue, Pittsburgh, PA (“Carnegie Mellon”) and NeuBase Therapeutics, Inc. a Delaware corporation, having a principal place of business at 2730 Sidney Street, Suite 300, Pittsburgh, PA 15203 (“Licensee”).
Ohr Pharmaceutical, Inc. S-4Convertible Note • March 8th, 2019 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • Delaware
THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
NOTE PURCHASE AGREEMENTNote Purchase Agreement • March 8th, 2019 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • Delaware
This Note Purchase Agreement, dated as of [●] (this “Agreement”), is entered into by and among NeuBase Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on the schedule of investors attached hereto as Schedule I (each an “Investor” and, collectively, the “Investors”), as such Schedule I may be amended in accordance with Section 7 hereof.
